AMGNAMGEN INC

Nasdaq amgen.com


$ 307.34 $ 7.01 (2.33 %)    

Wednesday, 08-May-2024 15:59:55 EDT
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 307.31
$ 300.32
$ 0.00 x 0
$ 0.00 x 0
$ 299.50 - $ 307.54
$ 206.75 - $ 327.16
2,858,665
na
164.72B
$ 0.54
$ 43.77
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-14-2024 12-31-2023 10-K
3 10-31-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 04-28-2023 03-31-2023 10-Q
6 02-09-2023 12-31-2022 10-K
7 11-04-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 04-28-2022 03-31-2022 10-Q
10 02-16-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-03-2021 06-30-2021 10-Q
13 04-28-2021 03-31-2021 10-Q
14 02-09-2021 12-31-2020 10-K
15 10-29-2020 09-30-2020 10-Q
16 07-29-2020 06-30-2020 10-Q
17 05-01-2020 03-31-2020 10-Q
18 02-12-2020 12-31-2019 10-K
19 10-30-2019 09-30-2019 10-Q
20 07-31-2019 06-30-2019 10-Q
21 05-01-2019 03-31-2019 10-Q
22 02-13-2019 12-31-2018 10-K
23 10-31-2018 09-30-2018 10-Q
24 07-27-2018 06-30-2018 10-Q
25 04-25-2018 03-31-2018 10-Q
26 02-13-2018 12-31-2017 10-K
27 10-26-2017 09-30-2017 10-Q
28 07-26-2017 06-30-2017 10-Q
29 04-27-2017 03-31-2017 10-Q
30 02-14-2017 12-31-2016 10-K
31 10-28-2016 09-30-2016 10-Q
32 07-29-2016 06-30-2016 10-Q
33 05-02-2016 03-31-2016 10-Q
34 02-16-2016 12-31-2015 10-K
35 11-02-2015 09-30-2015 10-Q
36 08-05-2015 06-30-2015 10-Q
37 04-27-2015 03-31-2015 10-Q
38 02-19-2015 12-31-2014 10-K
39 10-29-2014 09-30-2014 10-Q
40 08-05-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 amgen-ceo-robert-bradway-on-innovation-in-healthcare-says-hoping-to-have-innovation-approved-for-small-cell-lung-cancer-we-hope-to-help-rewrite-the-understanding-of-obesity-and-the-diseases-that-are-caused-by-it

- Milken Conference

 cathie-woods-ark-invest-snaps-up-354m-worth-of-shares-in-this-biopharma-company-following-positive-obesity-pipeline-update

As the demand for obesity drugs continues to surge, biopharma companies are eagerly seizing the opportunity to capitalize on th...

 stocks-rally-as-jobs-report-rekindles-rate-cut-hopes-apple-rockets-bitcoin-soars-above-61000-whats-driving-markets-friday

A weaker-than-expected jobs report sparked a widespread market rally in the last session of the week, as traders increased expe...

 rbc-capital-maintains-outperform-on-amgen-lowers-price-target-to-328

RBC Capital analyst Gregory Renza maintains Amgen (NASDAQ:AMGN) with a Outperform and lowers the price target from $332 to $...

 morgan-stanley-maintains-equal-weight-on-amgen-raises-price-target-to-310

Morgan Stanley analyst Terence Flynn maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $271...

 ubs-maintains-neutral-on-amgen-raises-price-target-to-307

UBS analyst Colin Bristow maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $284 to $307.

 william-blair-upgrades-amgen-to-outperform

William Blair analyst Matthew Phipps upgrades Amgen (NASDAQ:AMGN) from Market Perform to Outperform.

 amgen-outlook-is-bright-analyst-predict-obesity-focused-drug-potential-will-drive-shareholder-value

Amgen earnings beat estimates, and MariTide's promising Phase 2 results suggest significant differentiation from competitors.

 bmo-capital-maintains-outperform-on-amgen-raises-price-target-to-355

BMO Capital analyst Evan David Seigerman maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $3...

 wage-growth-slows--stock-market-celebrates-five-real-reasons-apple-is-running-up

To gain an edge, this is what you need to know today.

 barclays-upgrades-amgen-to-equal-weight-raises-price-target-to-300

Barclays analyst Carter Gould upgrades Amgen (NASDAQ:AMGN) from Underweight to Equal-Weight and raises the price target from...

 wall-street-looks-to-feed-off-apples-post-earnings-power-but-key-jobs-data-may-upset-the-cart-analyst-says-a-lot-of-these-clouds-will-lift-if-this-happens

Stocks look set to carry forward the upward momentum on Friday amid some earnings cheer, although a tinge of nervousness is evi...

 amgen-stock-adds-good-weight-after-ceos-update-on-experimental-drug-rivaling-ozempic-nixing-oral-weight-loss-candidate

MariTide, formerly AMG 133, is an injectable form of drug targeting two gut hormones — gastric inhibitory polypeptide receptor,...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION